Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 562K 522K 480K 900K 61.86M 916K 6.24M 2.43M 30.17M 2.4M 2.35M 105M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.12M 15.91M 14.63M 27.43M 1.89B 27.93M 190M 74.19M 920M 73.08M 71.5M 3.19B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI
20-05-29	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
20-04-22	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-04-21	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
20-03-30	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-01-08	Motion for Asset Sale Approved for Achaogen, Inc.	CI
19-12-29	Motion for Asset Sale Filed by Achaogen, Inc.	CI
19-09-24	Final DIP Financing Approved for Achaogen, Inc.	CI
19-08-29	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
19-08-13	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
19-07-29	Achaogen, Inc. Announces Management Changes	CI
19-07-23	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.83M 9.13M 8.4M 15.75M 1.08B 16.03M 109M 42.59M 528M 41.95M 41.05M 1.83B	8.73M 7.68M 7.13M 6.56M 12.3M 845M 12.52M 85.28M 33.26M 412M 32.77M 32.06M 1.43B
Net income	-126M -110M -103M -94.4M -177M -12.17B -180M -1.23B -479M -5.93B -472M -461M -20.59B	-187M -164M -152M -140M -263M -18.06B -268M -1.82B -711M -8.81B -700M -685M -30.56B
Net Debt	-143M -126M -117M -107M -201M -13.83B -205M -1.4B -544M -6.75B -536M -525M -23.41B	18.83M 16.56M 15.38M 14.15M 26.53M 1.82B 27.01M 184M 71.75M 889M 70.68M 69.16M 3.09B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news : Achaogen

Financials

Company Profile